Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE: Emiplacel (PLX-PAD) in Critical Limb Ischemia
NCT03006770Phase 3Completed
- Sponsor
- Pluri Inc.
- Start
- May 2017
- Primary completion
- Mar 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 9
01
Overview
A Phase 3 trial of PLX-PAD in critical limb ischemia (CLI), sponsored by Pluri Inc.. Started May 2017; status: completed.
02
Drugs
PLX-PAD
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03006770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006770.